CD8A and neoplasm: Several reports have also indicated that the expression of immune checkpoints, including Tim-3 and PD-1, render CD8+ T cells exhausted, and PD-1 blockade can not only improve CD8+ TIL activation and anti-tumor efficacy (41) but can also result in a CD8+ T-cell-dependent survival benefit (42).